Search

Your search keyword '"Bufalo, Donatella"' showing total 448 results

Search Constraints

Start Over You searched for: Author "Bufalo, Donatella" Remove constraint Author: "Bufalo, Donatella"
448 results on '"Bufalo, Donatella"'

Search Results

1. Notch3-regulated microRNAs impair CXCR4-dependent maturation of thymocytes allowing maintenance and progression of T-ALL

3. Correction: Notch3-regulated microRNAs impair CXCR4-dependent maturation of thymocytes allowing maintenance and progression of T-ALL

5. Upregulated expression of miR-4443 and miR-4488 in drug resistant melanomas promotes migratory and invasive phenotypes through downregulation of intermediate filament nestin

9. Oncosuppressive miRNAs loaded in lipid nanoparticles potentiate targeted therapies in BRAF-mutant melanoma by inhibiting core escape pathways of resistance

11. Bcl-2 family inhibitors sensitize human cancer models to therapy

12. Novel non-covalent LSD1 inhibitors endowed with anticancer effects in leukemia and solid tumor cellular models

13. SEMA6A/RhoA/YAP axis mediates tumor-stroma interactions and prevents response to dual BRAF/MEK inhibition in BRAF-mutant melanoma

15. LVI and DI-SPME Combined with GC/MS and GC/MS for Volatile Chemical Profile Investigation and Cytotoxic Power Evaluation of Essential Oil and Hydrolate from Cannabis sativa L. cv. Carmagnola.

19. Notch3-regulated microRNAs impair CXCR4-dependent maturation of thymocytes allowing maintenance and progression of T-ALL

22. microRNA-378a-5p iS a novel positive regulator of melanoma progression

25. First-in-Class Selective Inhibitors of the Lysine Acetyltransferase KAT8

26. Supplementary Figure 1 from Dual Promoter Usage as Regulatory Mechanism of let-7c Expression in Leukemic and Solid Tumors

27. Supplementary Figure Legends from Dual Promoter Usage as Regulatory Mechanism of let-7c Expression in Leukemic and Solid Tumors

28. Supplementary Figures 2 - 3 from Dual Promoter Usage as Regulatory Mechanism of let-7c Expression in Leukemic and Solid Tumors

29. Data from Dual Promoter Usage as Regulatory Mechanism of let-7c Expression in Leukemic and Solid Tumors

30. Supplementary Table 1 from Dual Promoter Usage as Regulatory Mechanism of let-7c Expression in Leukemic and Solid Tumors

31. Supplementary Figures and Table with legends from Predictive Signatures Inform the Effective Repurposing of Decitabine to Treat KRAS–Dependent Pancreatic Ductal Adenocarcinoma

32. Supplementary Materials and Methods from Predictive Signatures Inform the Effective Repurposing of Decitabine to Treat KRAS–Dependent Pancreatic Ductal Adenocarcinoma

33. Data from Predictive Signatures Inform the Effective Repurposing of Decitabine to Treat KRAS–Dependent Pancreatic Ductal Adenocarcinoma

34. Supplementary Figures 1-4 from CPTH6, a Thiazole Derivative, Induces Histone Hypoacetylation and Apoptosis in Human Leukemia Cells

35. Supplementary Methods, Figure Legends 1-4 from CPTH6, a Thiazole Derivative, Induces Histone Hypoacetylation and Apoptosis in Human Leukemia Cells

36. Correction: Zwergel et al. Novel Quinoline Compounds Active in Cancer Cells through Coupled DNA Methyltransferase Inhibition and Degradation. Cancers 2020, 12 , 447.

37. Bcl-2 family inhibitors sensitize human cancer models to target therapy

38. Phytochemicals as Immunomodulatory Agents in Melanoma

40. Semaphorin 5A drives melanoma progression: role of Bcl-2, miR-204 and c-Myb

41. Caspase-8 as a novel mediator linking Src kinase signaling to enhanced glioblastoma malignancy

42. Oncosuppressive miRNAs loaded in lipid nanoparticles potentiate targeted therapies in BRAF-mutant melanoma by inhibiting core escape pathways of resistance

43. Interleukin-8 in Colorectal Cancer: A Systematic Review and Meta-Analysis of Its Potential Role as a Prognostic Biomarker

49. Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models

Catalog

Books, media, physical & digital resources